Solaris Research Institute Launch
Solaris Research Institute (SRI) Launches through International Partnership and merger between Metro Pain Research Institute (MPRI) and Innovative Pain Treatment Solutions (IPTS)
San Diego, CA April 12, 2024
San Diego, CA, and Melbourne, Australia - Solaris Research Institute Inc., a newly launched institution in San Diego, California, will be a novel contract research organisation dedicated to advancing pain and spine research and development.
Under the visionary leadership of Krishnan Chakravarthy M.D., Ph.D., President of Solaris Research Institute (SRI), and Maja Green, Ph.D. CEO of SRI represents a significant step forward in advancing precision medicine solutions for pain management on a global scale.
Dr. Chakravarthy, a renowned figure in pain and spine management, expressed his enthusiasm about the merger, stating,
"There are very few research organisations with the scope, breadth and capabilities that Solaris Research Institute can offer and we are excited to launch this partnership with an outstanding leadership team. High quality clinical data, consistency and speed of execution are driving forces for sponsors, and we believe we offer something very unique to the pain management space.”
Maja Green, Ph.D., Chief Executive Officer of SRI stated
“We are looking to make a mark in the pain and spine field globally by providing state of the art software and database tools to sponsors that can drive the research and development of the space forward powerfully.”
Solaris Research Institute showcases enhanced research capabilities, streamlined clinical trial processes, and expanded access to diverse patient populations across the United States and Australia.
Paul Verrills M.D., Global Chief Medical Officer of the newly merged entity, emphasised the potential for groundbreaking advancements in pain intervention, saying,
"Together, we bring top-tier talent and strategic partnerships that will drive meaningful change in how we understand and treat pain conditions."
Key highlights of the merger include:
Combined expertise of world-renowned thought leaders in pain management.
Access to a centralized patient database facilitating efficient recruitment and trial completion.
Strategic partnerships with key industry leaders in both the medical device and pharmaceutical industry.
Proprietary software enabling decentralized trial recruitment across numerous clinical sites in the United States and worldwide.
The merger also aligns with Solaris Research Institute's commitment to innovation and collaboration, with a primary vision for excellence in pain and spine research and development.